Yield10 Bioscience announced that U.K.-based Rothamsted Research has granted to the Company an exclusive global, commercial license to advanced technology for producing sustainable omega-3 products in Camelina sativa. Yield10 is executing a plan to use engineered Camelina to commercially produce omega-3 oil and meal products targeting the aquafeed, petfood, and nutritional markets for omega-3 fatty acids. In consideration for the commercial license, Yield10 is expected to pay certain license fees, future milestone payments, and royalties based on commercialization of Rothamsted’s omega-3 technology. Producing omega-3 fatty acids in engineered Camelina may represent a way to enable a predictable, land-based supply of high-quality omega-3 oils to meet the growing global demand for eicosapentaenoic acid and docosahexaenoic acid. Currently, the primary source of EPA and DHA is ocean-caught fish, where omega-3 oil produced from anchovy harvest is the industry benchmark. Over the last few years, there has been increasing pressure on the supply of omega-3 oil due to over-fishing. The potential market opportunity for omega-3 fatty acids produced in Camelina includes use in pharmaceutical products, dietary supplements, and food and feed ingredients.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YTEN:
- Rothamsted Research Grants Yield10 Bioscience an Exclusive, Global Commercial License to Advanced Technology for Producing Omega-3 Products in Camelina
- Yield10 Bioscience Shareholders Decide on Stock and Leadership Matters
- Yield10 Bioscience Announces Addition of Camelina to INTERLINE® Herbicide Label
- Yield10 Bioscience announces addition of Camelina to INTERLINE label
- Yield10’s Reverse Stock Split: A Gamble on Liquidity and Market Appeal Set for May 2024
